Table 3 Non-hematological adverse events within 4 weeksa.

From: Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia

 

Total (%)

Grade 3–4(%)

CRS

39 (83.0)

11 (23.4)

ICANS

2 (4.3)

1 (2.1)

ALT/AST increased

10 (21.3)

2 (4.3)

CRE increased

2 (4.3)

0

APTT/PT prolonged

10 (21.3)

0

Fibrinogen decreased

5 (10.6)

0

Acidosis

1 (2.1)

0

Hypokalemia

4 (8.5)

1 (2.1)

Hypoglycemia

2 (4.3)

0

Cephalalgia

2 (4.3)

0

Myalgia

2 (4.3)

0

  1. aAccording to the CTCAE grading system by the United States National Cancer Institute38, and ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells39.
  2. CRS represents cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome, ALT alanine aminotransferase, AST aspartate aminotransferase, CRE creatinine, APTT activated partial thromboplastin time, PT prothrombin time.
  3. Source data is provided as a Source Data file or available at https://doi.org/10.6084/m9.figshare.13136078.v1.
Back to article page